Arthritis care & research
-
Arthritis care & research · Nov 2012
Reproducibility, validity, and responsiveness of the hip outcome score in patients with end-stage hip osteoarthritis.
To evaluate reproducibility, validity, and responsiveness of the Hip Outcome Score (HOS) in patients with end-stage hip osteoarthritis. ⋯ The HOS is reproducible and responsive when assessing patients with end-stage hip osteoarthritis in whom the items are relevant. However, based on the large proportion of missing data and the findings of the factor analysis, we cannot recommend this questionnaire for routine use in this target group.
-
Arthritis care & research · Nov 2012
Responsiveness of five outcome measurement instruments in total elbow arthroplasty.
To quantify and compare the sensitivity to change of 5 outcome instruments for the elbow joint. ⋯ The PREE was the most responsive instrument and can be recommended for every set of measures for elbow joint disorders. The pmASES was slightly less responsive but is a valid alternative. The examiner-assessed cmASES is affected by concerns regarding validity and was relatively less responsive. The DASH for comprehensive measurement of the entire upper extremity and the SF-36 for chronic pain conditions complete the assessment set.
-
Arthritis care & research · Nov 2012
Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study.
To estimate the minimum clinically important improvement (MCII) and patient acceptable symptom state (PASS) values for 4 generic outcomes in 5 rheumatic diseases and 7 countries. ⋯ This work allows for promoting the use of values of MCII (15 of 100 for absolute improvement, 20% for relative improvement) and PASS (40 of 100) in reporting the results of trials of any of the 5 involved rheumatic diseases with pain, patient global assessment, physical function, or physician global assessment used as outcome criteria.
-
Arthritis care & research · Nov 2012
Comparative StudyComparison of health-related outcomes for arthritis, chronic joint symptoms, and sporadic joint symptoms: a population-based study.
To examine predictors and health outcomes for individuals reporting arthritis, chronic joint symptoms (CJS), or sporadic joint symptoms (SJS) compared to those without arthritis or joint symptoms. ⋯ CJS were reported by 10% of the adult population. Similarities in outcomes to arthritis suggest that CJS have a substantial impact in the population, and that arthritis management advice is likely needed for this group.
-
Arthritis care & research · Nov 2012
Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica.
The interleukin-6 pathway is up-regulated in giant cell arteritis (GCA), Takayasu arteritis (TA), and polymyalgia rheumatica (PMR). We retrospectively assessed the outcomes of 10 patients with relapsing/refractory GCA, TA, or PMR treated with tocilizumab (TCZ). ⋯ TCZ therapy led to clinical and serologic improvement in patients with refractory/relapsing GCA, TA, or PMR. The demonstration of persistent large-vessel vasculitis at autopsy of 1 patient who had shown a substantial response requires close scrutiny in larger studies.